Remote ischemic conditioning for the prevention of stroke-associated pneumonia (RICA-2): protocol for a multicenter, prospective, randomized, double-blind, sham-controlled phase III trial
Abstract
Stroke-associated pneumonia (SAP) is one of the most common complications in acute ischemic stroke (AIS) patients, affecting 8.5% to nearly 30% of cases and significantly impacting both mortality and long-term survival. As it is closely related to worse outcome, exploring effective preventive strategies, such as remote ischemic conditioning (RIC), is essential for reducing SAP incidence and improving patient outcomes. This study aims to compare the efficacy and safety of RIC for preventing SAP in patients with ischemic stroke within 24 h of symptom onset. RICA-2 is a multicenter, randomized, double-blind, parallel-controlled, phase III clinical trial in China. This study will enroll an estimated 1650 patients aged ≥ 18 years within 24 h after AIS symptom onset, with National Institutes of Health Stroke Scale ⩾ 4. The patients will be randomly assigned to RIC or Sham-RIC (1:1) and will be treated with cuff inflation at 200 mmHg or 60 mmHg, respectively. This procedure will be administered twice daily for seven consecutive days. The primary efficacy endpoint is SAP incidence rate. Safety incidence will be recorded and reported. RIC has broad clinical application prospects and may play a preventive role in stroke-related pneumonia. RICA-2 is designed to verify whether RIC treatment can serve as an adjuvant therapy for preventing stroke-associated pneumonia and to identify safety concerns. ClinicalTrials.gov NCT05982015. Registered on January 22, 2024.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 1,650 participants or records.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.